Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Tissue Regenix Group Plc LSE:TRX London Ordinary Share GB00B5SGVL29 ORD 0.1P
  Price Change % Change Share Price Shares Traded Last Trade
  0.005 1.64% 0.31 98,534,357 16:35:27
Bid Price Offer Price High Price Low Price Open Price
0.31 0.32 0.315 0.305 0.305
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 13.03 -7.66 -0.60 22
Last Trade Time Trade Type Trade Size Trade Price Currency
17:07:44 O 44,566,214 0.30 GBX

Tissue Regenix (TRX) Latest News

More Tissue Regenix News
Tissue Regenix Takeover Rumours

Tissue Regenix (TRX) Discussions and Chat

Tissue Regenix Forums and Chat

Date Time Title Posts
14/8/202015:32Tissue Regenix delivering practical solutions to real clinical issues5,915
26/5/202013:31Torex with Charts & News14
15/1/202007:09TOREX 2007 - THE TILLS RING AT LAST13
14/1/202020:51Terrane Minerals- Cu explorer, trading in Canada17
12/11/201915:05Fair Value ?4

Add a New Thread

Tissue Regenix (TRX) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
2020-08-14 16:15:000.3044,566,214133,698.64O
2020-08-14 16:07:440.315,729,70017,762.07O
2020-08-14 15:35:270.3121,05465.27UT
2020-08-14 15:29:540.311,000,0003,136.00O
2020-08-14 15:26:390.32500,0001,597.50O
View all Tissue Regenix trades in real-time

Tissue Regenix (TRX) Top Chat Posts

DateSubject
14/8/2020
09:20
Tissue Regenix Daily Update: Tissue Regenix Group Plc is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker TRX. The last closing price for Tissue Regenix was 0.31p.
Tissue Regenix Group Plc has a 4 week average price of 0.30p and a 12 week average price of 0.28p.
The 1 year high share price is 4.15p while the 1 year low share price is currently 0.28p.
There are currently 7,032,985,756 shares in issue and the average daily traded volume is 17,963,169 shares. The market capitalisation of Tissue Regenix Group Plc is £21,802,255.84.
17/7/2020
15:21
cerrito: I am not expecting any news as the situation was spelt out clearly enough when they announced their fundraising. An article in the FT a couple of days back makes the point that the fewer elective surgery operations in the US are doing wonders for the share price of the US health insurers.
10/6/2020
09:38
channel pirate: If we get the chance to add anywhere near 0.25p then I will add, but I have spent so much buying this companies shares as they have descended over the past 5+ years that I will just sit and wait and hope I have not "popped my clogs" by the time we get a decent share price. Good Luck All.
22/5/2020
15:57
isletower2: When the RNS states that the Directors are going in for £620,000 worth of shares in a 76% discounted placing, you do not need to be Einstein to work out that prospects for the share price are probably better than neutral... Delighted to be a shareholder in this for the first time
21/5/2020
20:53
holdingtight: So we need this cash injection to facilitate investments and developments that create at least a 4 fold increase in the value of the business (using closing price) just to stand still.Solving the near term working capital requirement, set against the suppressed share price, could arguably double the value. So we need a 2.5 times increase from there.Not out of reach, but of course this is no longer a ten bagger - if it ever was then it is still potentially a 2 bagger though !
21/5/2020
17:51
longshanks: You need to pay by a debit card - so yes - need to have liquid funds in a bank account. Looks like this OO doesn't come with any EIS benefits which is a bit of a downer for me. Price will plummet in the morning but the business looks like one worth saving so I am sure it will raise the money needed. That itself justifies some kind of stake. They need to do a capital reorganisation as part of this to drop the nominal value of the shares. I would have thought they would look to do a 100:1 consolidation at the same time to give the share price some back bone. Overall for me - the positives outweigh the negatives. Whilst I don't typically like 'penny shares' I am in for a few and will suck and see.
11/5/2020
08:38
channel pirate: The company MUST get their share price up as it's a sitting duck to be bought up at this ridiculous low price. I wouldn't mind seeing the company bought up later in a few years time, let's say at £5 a share would do me !!
22/1/2020
09:52
traderguy1: Anyone with an ounce of common sense would know if a placing was going to happen it would have happened today along with the trading update and higher share price. It’s obvious they are looking at other options. NOT A PLACING. This company will do well, by year end the share price will be much much higher than now. TRX is going to do well... Ignore the idiots
15/1/2020
22:24
the stigologist: Good post from a.n.other forum Anyhow now onto TRX. This company has spent £10’s millions developing their FDA approved portfolio. The market Tissue Regenix operate it is significantly in growth. The ambient stable technology offered by TRX is a huge benefit as it removes the expensive chilled distribution costs relied upon by their competitors. Tissue Regenix is a young company with a CFO now acting as CEO so don’t expect fireworks from their PR team. He is calculated and knows what needs to be done to recover the MCAP to £100m. Now look over the Atlantic. The majority of sales are in the USA along with production. This would make a perfect marriage with one of the major distributors like Medline or McKesson, who are alway looking for new tech companies to buy. I personally hope this doesn’t happen, as within a year I believe the share price will be plus 10p. Finance update should be black and white. MIDCAP will be the ongoing partner short and medium term. They just want TRX to spend their own money before they spend theirs. (RNS could have been worded better). With all focus on America we forget the ROW sales opportunities. Following the positive move to outsource some of the less critical portfolio, this will increase availability and allow the business to open up new markets. Don’t forget we can buy tomorrow thanks to Woodford. That is the only reason. I am making the most of this and will continue to buy and hold. For me this is one of the most exciting companies on AIM. I feel for those who lost money on DEB and more recently LEK. In the world of AIM their are plenty of wasps, but once in a while you find the Queen Bee. Good luck all genuine holders.
01/1/2020
16:39
holycow1: So you are saying that Midcap have said to TRX go and get a placing before we part with our money? Their are many ways to restructure a company. hxxps://corporatefinanceinstitute.com/resources/knowledge/finance/recapitalization/ Attention to... Leveraged Recapitalization In a leveraged recapitalization, the company replaces part of its equity with additional debt and thereby changes its capital structure. One form of leveraged recapitalization might be a company issuing bonds to raise money. A company may resort to leveraged recapitalization if its share price declines. In this case, the company may issue debt securities to fund buying back its outstanding shares in the market. By reducing the number of outstanding shares, the company expects to increase the per share price.
14/11/2019
07:06
irondick: LSE:TRX Tissue Regenix Share News (TRX) 2 Follow TRX Share Name Share Symbol Market Type Share ISIN Share Description Tissue Regenix Group Plc LSE:TRX London Ordinary Share GB00B5SGVL29 ORD 0.5P Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade 0.00 0.0% 1.125 1.10 1.15 0.00 0.00 0.00 0.00 00:00:00 Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m) Pharmaceuticals & Biotechnology 11.6 -8.9 -0.7 - 13 Print Alert Tissue Regenix Group PLC Updated loan facility agreement with MidCap 14/11/2019 7:01am UK Regulatory (RNS & others) Tissue Regenix (LSE:TRX) Intraday Stock Chart Today : Thursday 14 November 2019 Click Here for more Tissue Regenix Charts. TIDMTRX RNS Number : 3497T Tissue Regenix Group PLC 14 November 2019 This announcement contains inside information Tissue Regenix Group plc Updated loan facility agreement with MidCap Leeds, 14 November 2019 - Tissue Regenix Group (AIM:TRX) ("Tissue Regenix" or the "Company") the regenerative medical devices company, announces the terms of a revised agreement ("Agreement") that it has entered into with MidCap Financial Trust ("MidCap") with regard to the term loan credit facility (the "Term Loan") and revolving credit facility (the "RCF") (together, the "Facilities"). This follows the Company's announcement on 11 November 2019. Further details of the Facilities are contained in the Company's announcement on 4 June 2019. Following engagement with MidCap the Company has successfully renegotiated the Term Loan, agreeing an immediate repayment of $5.5 million of the outstanding Term Loan ("Repayment"). Under the terms of the Agreement, MidCap has agreed to waive the prepayment fee and defer a portion of the exit fee due thereunder until the earlier of the date upon which the Term Loan is repaid or the maturity date. The remaining balance of $2.0 million of the Term Loan currently drawn down by the Company will remain in place ("Tranche One"). The Company will also continue to have access to draw down the remainder of the RCF, which is calculated based on the underlying inventory and receivables on the balance sheet and eligibility thereof. In addition, MidCap has agreed to suspend its testing of the financial banking covenants until 30 June 2020, when it will recommence with reduced revenue targets. MidCap has agreed to add the repaid $5.5 million of Tranche One to its commitment amount under tranche two of the Term Loan, which consisted of $5.0 million and now consists of $10.5 million ("Tranche Two"). Access to Tranche Two and the final tranche of $2.5 million ("Tranche Three") of the Term Loan remain in place, however the drawdown of these tranches is now subject to MidCap's discretion and satisfactory recapitalisation of the Company at that time. The repayment of the outstanding principal of the Term Loan will begin on 1 July 2020 and will amortise on a straight-line basis across 48 months.
Tissue Regenix share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
LSE
TRX
Tissue Reg..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20200814 23:07:17